Qnovia's Innovative NRT Offers New Hope for Smokers in First Clinical Trial Qnovia has announced positive Phase 1 trial results for its inhaled nicotine replacement therapy, RespiRx™, potentially revolutionizing smoking cessation methods.

Qnovia's Innovative NRT Offers New Hope for Smokers in First Clinical Trial #United_States #Irvine #Qnovia #RespiRx #Nicotine_Replacement

Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development Qnovia, Inc. has successfully raised $16 million in Series B financing aimed at advancing its RespiRx™ Nicotine Inhaler for smoking cessation.

Qnovia Secures $16 Million in Series B Financing to Enhance Nicotine Inhaler's Development #United_States #Richmond #Qnovia #RespiRx #Nicotine_Inhaler